{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:28:37Z","timestamp":1791242917384,"version":"4.1.0"},"reference-count":34,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Obesity is becoming a global health epidemic. Brown and \u201cbeige\u201d adipose tissue may produce heat, leading to energy expenditure enhancement and weight loss. Mirabegron, a selective \u03b23-adrenergic receptor agonist, has been found to be effective as a brown adipose tissue activator, a \u201cbeige\u201d cells stimulator and a metabolic homeostasis controller in animal and human studies. Although in animal studies, administration of mirabegron led to obesity improvement, significant weight loss in obese patients after mirabegron treatment has not been demonstrated so far, which may be associated with the too-short duration of the trials and the small number of participants in the studies. In humans, the most effective treatment for adipose tissue stimulation was high doses of mirabegron; however, cardiovascular side effects may limit the use of such doses, so the long-term safety must be evaluated. In cases of tachycardia or blood pressure elevation, the co-administration of a \u03b21-adrenergic receptor blocker may be useful. It should be checked whether smaller doses of mirabegron, taken for a longer time, will be sufficient to stimulate brown and \u201cbeige\u201d adipose tissue, leading to weight loss. The introduction of mirabegron into obesity treatment in the future will require long-term trials with larger numbers of subjects, to assess mirabegron efficacy, tolerability, and safety.<\/jats:p>","DOI":"10.3390\/jcm12216897","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T02:05:07Z","timestamp":1698890707000},"page":"6897","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Mirabegron, a Selective \u03b23-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7905-2871","authenticated-orcid":false,"given":"Anna Maria","family":"D\u0105browska","sequence":"first","affiliation":[{"name":"Department of Toxicology, Medical University of Lublin, Jaczewskiego Street 8b, 20-090 Lublin, Poland"},{"name":"Endocrinology Outpatient Clinic, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Dudka","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Medical University of Lublin, Jaczewskiego Street 8b, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cmet.2014.12.009","article-title":"Activation of human brown adipose tissue by a \u03b23-adrenergic receptor agonist","volume":"21","author":"Cypess","year":"2015","journal-title":"Cell. Metab."},{"key":"ref_2","first-page":"e207","article-title":"The combined effect of metformin and mirabegron on diet-induced obesity","volume":"4","author":"Zhao","year":"2023","journal-title":"Med. Comm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1111\/dom.14120","article-title":"The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men","volume":"22","author":"Nahon","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/jpet.118.255778","article-title":"Beneficial Metabolic Effects of Mirabegron In Vitro and in High-Fat Diet-Induced Obese Mice","volume":"369","author":"Hao","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1172\/JCI131126","article-title":"Chronic mirabegron treatment increases humaan brown fat, HDL-cholesterol and insulin sensitivity","volume":"130","author":"Johnson","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1080\/14656566.2016.1233177","article-title":"Beta3-adrenoreceptor agonist mirabegron\u2014A potential antiobesity drug?","volume":"17","author":"Hainer","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/oby.21134","article-title":"Diet-Induced Obesity Causes Insulin Resistance in Mouse Brown Adipose Tissue","volume":"23","author":"Cypess","year":"2015","journal-title":"Obesity"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1172\/JCI136476","article-title":"Might \u03b23-adrenergic receptor agonists be useful in disorders of glucose homeostasis?","volume":"130","author":"Flier","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e143650","DOI":"10.1172\/jci.insight.143650","article-title":"Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism","volume":"6","author":"Finlin","year":"2021","journal-title":"JCI Insight"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e139160","DOI":"10.1172\/jci.insight.139160","article-title":"\u03b23-Adrenergic receptors regulate human brown\/beige adipocyte lipolysis and thermogenesis","volume":"6","author":"Cero","year":"2021","journal-title":"JCI Insight"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdi.13509","article-title":"Body-weight-independent glucose-lowering effect of the b3-adrenergic receptor agonist mirabegron in humans","volume":"12","author":"Waki","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e3594","DOI":"10.1002\/dmrr.3594","article-title":"Brown adipose tissue and regulation of human body weight","volume":"39","author":"Harb","year":"2023","journal-title":"Diabetes Metab. Ress. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1172\/JCI134892","article-title":"The \u03b23-adrenergic receptor agonist mirabegron improves glucose homeostatsis in obese humans","volume":"130","author":"Finlin","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e121510","DOI":"10.1172\/jci.insight.121510","article-title":"Human adipose beiging in response to cold and mirabegron","volume":"3","author":"Finlin","year":"2018","journal-title":"JCI Insight"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00643","DOI":"10.1002\/prp2.643","article-title":"The metabolic effects of mirabegron are mediated primarily by \u03b23-adrenoceptors","volume":"8","author":"Dehvari","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1111\/bph.14121","article-title":"Mirabegron: Potential off target effects and uses beyond the bladder","volume":"175","author":"Dehvari","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2337\/db18-0462","article-title":"Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a b3-Adrenergic Receptor Agonis","volume":"67","author":"Baskin","year":"2018","journal-title":"Diabetes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/1440-1681.13566","article-title":"The effects of mirabegron on obesity-induced inflammation and insulin resistance are associated with brown adipose tissue activation but not beiging in the subcutaneous white adipose tissue","volume":"48","author":"Calmasini","year":"2021","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2042018811398517","article-title":"Challenges in \u03b23-adrenoceptor agonist drug development","volume":"2","author":"Arch","year":"2011","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_20","first-page":"R1212","article-title":"Mechanisms of the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker-ZDF rats","volume":"274","author":"Liu","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/dom.13516","article-title":"Acute metabolic and cardiovascular effects of mirabegron in healthy individuals","volume":"21","author":"Loh","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00210-012-0824-1","article-title":"Pharmacological profile of \u03b23-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome","volume":"386","author":"Igawa","year":"2013","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejogrb.2015.11.018","article-title":"Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females","volume":"196","author":"Krhut","year":"2016","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00210-012-0821-4","article-title":"In vitro and in vivo pharmacological profile of the selective \u03b23-adrenoceptor agonist mirabegron in rats","volume":"386","author":"Hatanaka","year":"2013","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.molcel.2021.06.024","article-title":"Cryo-EM structure of the \u03b23-adrenergic receptor reveals the molecular basis of subtype selectivity","volume":"81","author":"Nagiri","year":"2021","journal-title":"Mol. Cell."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100674","DOI":"10.1016\/j.curtheres.2022.100674","article-title":"Selectivity and Maximum Response of Vibegron and Mirabegron for \u03b23-Adrenergic Receptors","volume":"96","author":"Brucker","year":"2022","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bph.13367","article-title":"Mirabegron relaxes urethral smooth muscle by a dual mechanism involving \u03b23 -adrenoceptor activation and \u03b11 -adrenoceptor blockade","volume":"173","author":"Alexandre","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"107094","DOI":"10.1016\/j.vph.2022.107094","article-title":"Mirabegron relaxes arteries from human visceral adipose tissue through antagonism of \u03b11-adrenergic receptors","volume":"146","author":"Schinzari","year":"2022","journal-title":"Vascul. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/366740a0","article-title":"Development of obesity in transgenic mice after genetic ablation of brown adipose tissue","volume":"366","author":"Lowell","year":"1993","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1210\/endo.137.1.8536614","article-title":"Decreased brown fat markedly enhances susceptibility to diet-induced obesity, diabetes, and hyperlipidemia","volume":"137","author":"Hamann","year":"1996","journal-title":"Endocrinology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fendo.2020.00191","article-title":"Metformin and its benefits for various diseases","volume":"11","author":"Lv","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13318-016-0350-5","article-title":"Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives","volume":"42","author":"Krauwinkel","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e14779","DOI":"10.14814\/phy2.14779","article-title":"Mirabegron: The most promising adipose tissue beiging agent","volume":"9","author":"Bel","year":"2021","journal-title":"Physiol. Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6897\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:15:52Z","timestamp":1760130952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":34,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jcm12216897"],"URL":"https:\/\/doi.org\/10.3390\/jcm12216897","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}